Publication/Presentation Date

10-29-2020

Abstract

The treatment of metastatic melanoma has changed dramatically in the last decade with the introduction of immunotherapy and targeted therapy. A futile disease in the past is now treated with various options, resulting in improvement in progression-free and overall survivals, along with improvement in the quality of life. Having said that, the majority of patients with metastatic melanoma eventually succumb to the disease. Molecular profiling of each tumor in the advanced stage is standard of care now, as this would lead to individualized treatment options for each patient. Here, we present a rare case of fibroblast growth factor receptor 3 (FGFR 3) amplified metastatic melanoma, treated rather unconventionally with FGFR 3 inhibitor erdafitinib.

Volume

12

Issue

10

First Page

11231

Last Page

11231

ISSN

2168-8184

Disciplines

Medicine and Health Sciences

PubMedID

33269159

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Radiation Oncology

Document Type

Article

Share

COinS